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S262 Poster Session Imalignant group, the cumulative incidence of 90% donor chimerism
at +100 days was only 64.6%, and the percentage of full or mixed chi-
merism at one year was 76% and 24%. Our data show that while
RIC-HSCT leads to durable and full donor chimerism in the major-
ity of patients, some experience engraftment instability, which could
respond to timely intervention with withdrawal of immune suppres-
sion and/or DLI. Frequent and long-term monitoring of donor chi-
merism would offer the opportunity to positively impact the clinical
course of these patients.
Table 1. Patient Characteristics (n588)Median Age7
57.3 years
(20 days - 21 years)M/F 47/41
Diagnoses
Malignant 40
ALL/AML/MDS 13/4/7
CML 5
Relapsed HD 3
Other 8
Non-malignant 48
SCID 13
SAA 7
Other 28
HPC Source
Matched Sibling/Related 34
MUD/MM Related 22
MMUD 32
PBSC/Marrow/Cord 74/2/12
Median Cell Dose
CD 34+/Kg  10^6 (0.12 - 37.5)
MNC/Kg  10^8 (0.27 - 9.5)
Conditioning Regimen
Fludarabine/Busulfan/ATG 57
Fludarabine/Busulfan/ECP 19
Fludarabine/Busulfan 5
Other fludarabine 7296
CLINICAL RELEVANCE OF SERIAL CHIMERISM ANALYSIS AFTER ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
WITH NON-MALIGNANT DISEASES
Park, M., Koh, K.N., Kim, B.E., Choi, E.S., Shin, H., Im, H.J., Seo, J.J.
Asan Medical Center Children’s Hospital, University of Ulsan College of
Medicine, Seoul, Korea
Background: In allogeneic hematopoietic stem cell transplantation
(HSCT), the effect of chimerism often remains unclear andmay have
different implications in various diseases. We performed retrospec-
tive study to evaluate chimerism status and transplant outcome in
children with non-malignant diseases.
Patients & Methods: Between September 1999 and January 2010
we analyzed the data of 42 transplants performed in 40 children
with nonmalignant diseases. Short tandem repeat polymerase chain
reaction (STR-PCR) was used to evaluate chimerism. Mixed chime-
rism (MC) was defined as . 1% recipient cells.
Results:MCwas detected in 17 (40%) transplants. Of these 17 cases,
8 developed decreasingMC, 6 persisted with low-proportions of au-
tologous cells below 30% (stable MC) and 3 showed $ 30% recipi-
ent signals in two consecutive samples (high MC). Among 4 graft
failures, one showed autologous recovery. The 2 patients with graft
failure received the second transplant, of whom one is alive in remis-
sion. The remaining one received donor lymphocyte infusion (DLI)
due to the high MC, which subsequently resulted in further increase
of autologous cells. The incidence of MC was not different statisti-
cally between reduced intensity conditioning andmyeloablative con-
ditioning. The probabilities of achieving complete donor chimerism
(CC) at 1, 3, 6 and 12 months after HSCT were 70.0%, 68.3%,
75.7% and 78.8%, respectively. Overall probability of grade II–IV
acute GVHD was significantly higher in CC group compared to
the MC group (57.1% vs. 11.8%, p 5 0.006). High MC was associ-
ated with graft failure (p 5 0.004). At a median follow-up of 36
months, the 3-year overall survival and event-free survival after
HSCT for non-malignant diseases in children were 90.0% and87.2%, respectively. There was no significant survival difference be-
tween CC and MC. Patients with high MC showed inferior survival
rate compared to the patients with stable or decreasing MC (33.3 vs.
92.3%, p 5 0.014).
Conclusions: In this study, overall incidence of MC was 40% after
transplantation for non-malignant diseases.MCmay indicate a toler-
ant state in transplanted individuals with a decreased incidence of
acute GVHD. However, high MC was at risk of graft failure and
also associated with lower survival rate. Sequential chimeric status
could give important information on post-transplant course after
HSCT for non-malignant diseases.297
FOLINIC ACID RESCUE INCREASES ABILITY TO DELIVER FULL COURSE OF
METHOTREXATE GVHD PROPHYLAXIS FOR PEDIATRIC HSCT RECIPI-
ENTS
Hudspeth, M., Heath, T., Chiuzan, C., Garrett-Mayer, E., Nista, E.,
Burton, L., Ragucci, D. Medical University of South Carolina, Charleston,
SC
Background: Cyclosporine and short-course MTX are commonly
used for GVHD prophylaxis in pediatric BMT. Day 11 MTX has
been administered to\ 75 % of patients in adult studies due to se-
vere mucositis or organ dysfunction. Omission of day 11 MTX is as-
sociated with an increased risk of GVHD. Folinic acid may
ameliorate MTX toxicity.
Methods:We conducted a retrospective chart review of all pediatric
patients from January 2000- July 2010 who received cyclosporine
and short course MTX for GVHD prophylaxis. One patient was ex-
cluded formissing records. Patients prior to July 2007 did not receive
folinic acid (N 5 18). All patients thereafter received folinic acid 10
mg/m2 IV 12 hours after each MTX dose (N5 29). Logistic regres-
sion was used to estimate the ORmeasuring the association between
folinic acid use and receipt of day 11MTX, adjusting for preparative
regimen, graft source, and disease status at BMT. Kaplan-Meier sur-
vival curves with a log-rank test were used to determine relapse-free
survival. Statistical significance was accepted at p\ 0.05.
Results: Patients who received folinic acid rescue were significantly
more likely to receive day 11MTX.(OR 10.42, 95%CI 1.21-262.27)
However, there was no significant difference inGrade III-IVGVHD
between the patients who received folinic acid rescue and those who
did not. (OR 1.15, 95% CI 0.08-18.14). Folinic acid rescue did not
impact relapse-free survival (P 5 0.82).
Conclusion:Although folinic acid rescue increased the likelihood of
receiving the day 11 MTX, this did not translate into a reduction of
Grade III-IV GVHD. However, there was also no difference in re-
lapse-free survival to suggest a deleterious effect on disease control,
which has been cited as a concern by some groups. Increased likeli-
hood of receiving day 11MTX does suggest that folinic acid amelio-
rates MTX toxicity, such as severe mucositis. Folinic acid rescue for
short course MTX should be studied in a prospective, randomized
fashion.298
DIGITAL MULTIPLEXED QUANTIFICATION OF BOTH T-CELL RECEPTOR
b-CHAIN AND a-CHAIN DIVERSITY IN T CELLS USING THE NANOSTRING
NCOUNTER ASSAY SYSTEM
Maiti, S.N.1, Zhang, M.2, Bernatchez, C.2, Torikai, H.1, Kellar, D.1,
Gibbons, H.1, Hernandez, J.2, Andersson, H.1, Huls, H.1, Lee, D.1,
Hwu, P.2, Radvanyi, L.2, Cooper, L.1 1M.D. Anderson Cancer Center,
Houston, TX; 2M.D. Anderson Cancer Center, Houston, TX
Measurement and skewing ofT-cell receptor (TCR)a and b diver-
sity in the tumor-bearing host (i) engrafted with allogeneic hemato-
poietic stem cells and/or (ii) after vaccination or adoptive T-cell
transfer, are used for monitoring the effect of immunotherapies.
TCR diversity is mostly concentrated within the third complemen-
tarity-determining region (CDR3) of a and b chains. Currently avail-
able methods for measuring diversity are primarily limited to
TCRVb usage and are (i) flow-cytometric detection by using
Poster Session I S263antibody panel against TCRVb, (ii) CDR3 length spectratyping by
semi-quantitative RT-PCR, and (iii) DNA sequencing of the rear-
ranged CDR3 regions. Although these methods can detect oligoclo-
nal expansion of T cells they are costly, labor-intensive, and require
substantial amount of sample. Here, we adapted the newly-devel-
opedNanostring nCounter Analysis System to quantify gene expres-
sion of 45 TCRVb and 44 TCRVa gene families in a single non-
enzymatic reaction from a small number of T cells. Two sequence-
specific gene probes, one mRNA target sequence-specific capture
probe, and a second mRNA target sequence-specific fluorescent-la-
beled color-coded probe were produced for each of the TCR genes.
These were used to determine TCRVb and TCRVa usage based on
profiling the 99 V region families of T cells from healthy volunteers
by nCounter System and a subset of these data were validated by flow
cytometry with TCRVb-specific mAb. Subsequently, we analyzed
clinical samples obtained from 10 patients with advanced melanoma
treated with ex vivo propagated tumor infiltrating lymphocyte (TIL)
therapy. To validate this data set, the TCRVb panel analysis ob-
tained from nCounter assay of these samples agreed with CDR3
DNA sequencing data. This is the first time that digital mRNA pro-
filing for TCRVb and TCRVa has been undertaken without requir-
ing cDNA synthesis, enzymatic reactions, or mAb usage. Our
approach requires just a small amount of total RNA and at $1.40/
gene, this assay is cost-effective. It is anticipated that this approach
will be of significant interest to immunologists seeking tomanipulate
the human immune system.299
PRE-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT MINIMAL RESID-
UAL DISEASE PREDICTS POST-TRANSPLANT RELAPSE IN PEDIATRIC
ACUTE MYELOBLASTIC LEUKEMIA
Ammon, K., Cowan, M.J., Horn, B., Dvorak, C.C. Univeristy of Califor-
nia San Francisco Benioff Children’s Hospital, San Francisco, CA
Minimal residual disease (MRD) is well-established as a prognostic
factor in ALL, and multiple studies suggest that the existence of
MRD likely also portends a worse outcome in AML. Although pa-
tients with ALL appear to have very high relapse rates when trans-
planted with detectable MRD, it is not known whether molecular
remission prior to HCT for AML is important in terms of relapse
and survival, or whether morphologic remission is sufficient.
Methods:A retrospective reviewwas performed of pediatric patients
with AML undergoing myeloablative allogeneic transplants at our
center from 2000-2010. Bone marrow pathology reports, including
flow cytometry reports when available, from within 2 weeks prior
to start of conditioning were reviewed. Patients were grouped by
morphologic remission status (remission defined by blasts\ 5%)
and by MRD status. MRD was defined by the presence of $ 0.1%
blasts by flow cytometry, or positive cytogenetics with\ 5% blasts.
Event-free survival (EFS), relapse incidence (RI), and transplant-re-
lated mortality (TRM) were evaluated by Kaplan-Meier survival
analysis using Stata 11.1 (College Station, TX). The logrank test
was used to calculate p-values.
Results: 39 pediatric patients with AML underwent 42 HCTs. 24
patients are alive and well, 8 died due to disease, 5 died without re-
lapse, and 2 are alive with relapsed disease. Median follow up was
23 months (range: 1-126 months). 6 patients were not in morpho-
logic remission prior to transplant. Of 23 patients inmorphologic re-
mission with evaluable MRD, 16 were MRD negative at time of
HCT (MRD\ 0.1%). There was no difference between patients
who were MRD negative or positive in terms of gender, age at trans-
plant, donor type, stem cell source, or remission status (first remis-
sion vs. other). Comparing MRD positive patients with MRD
negative patients, the EFS was 57% vs. 81% (p 5 0.3), and TRM
was 0% vs. 13% (p 5 0.4), respectively. RI post-transplant was
43% (95% CI, 15-85%) for those patients who had evidence of
MRD, but only 6% (95% CI, 0-50%) for those who achieved
a deeper remission (p 5 0.048).
Conclusions: A pre-HCT MRD level of $ 0.1% is predictive of
post-allogeneic HCT risk of relapse in pediatric AML. This study
did not have the power to detect a statistically significant difference
in OS, EFS, or TRM based on pre-HCTMRD. Larger prospective
trials are needed to fully evaluate the implications of using pre-HCT
MRD for treatment decisions.300
THE IMPACT OF IRON OVERLOAD BEFORE TRANSPLANT AND THE
NATURAL EVOLUTION OF FERRITIN AFTER TRANSPLANT ON CHILD-
HOOD ALLOGENIC SCT
Maeba, H., Nishimura, R., Kuroda, R., Mase, S., Araki, R., Yachie, A.
Kanazawa University, Kanazawa, Ishikawa, Japan
Iron overload before hematopoietic stem cell transplantation
(HSCT) is known to be associated with non-relapse mortality, infec-
tions and sinusoidal obstructive disease (SOS). Therefore some
groups reported that iron-chelating therapy beforeHSCTmight im-
prove the outcome. After HSCTmost recipients eventually transfu-
sion independent, howevermore than half of HSCT adult long-term
survivors had above normal ferritin level and requirements of iron-
chelating therapy for such patients is still controversial. To apply
the above content mainly made by adult patients to childhood cases,
we investigated the association of iron overload with complications
and survival after allogeneic HSCT in childhood hematological dis-
orders other than thalassemia (n 5 37) using ferritin as a surrogate
marker of iron overload. We also evaluated the association between
the natural evolution of serum ferritin after HSCT and late compli-
cations (n5 33). First we performed subgroups analysis for 2 groups
by serum ferritin (F) level before HSCT (F. 1000 ng/ml, F\1000
ng/ml). There were no statistical differences in acute GVHD, infec-
tions, SOS, mortality and chronic GVHD between two groups be-
fore HSCT. Next at the time of 1-year post transplant, 3 out of 37
(8%) long-term HSCT survivors had high ferritin level. One of
them returned to normal range without iron-chelating therapy 2
years after HSCT. The two remaining patients showed persistent
hyperferritinemia (1000-3000) with/witout liver dysfuction. More
specific and sensitive methods to assess iron stores such as liver bi-
opsy should be performed in such patients, even in pediatric patients.
We concluded that high level of serum ferritin before HSCT is not
a prognostic factor in childhood patients undergoing HSCT, unlike
adult cases. Frequency of persistent hyperferritinemia in childhood
HSCT recipients wasmuch less than that in adult cases reported pre-
viously, probably due to more iron requirements in children to grow
up. The impact of iron overload and natural evolution of ferritin on
allogeneic childhood HSCT differ from adult HSCT.301
STEM CELL TRANSPLANT FOR HLH: SINGLE INSTITUTION SERIES
Allen, C., Martinez, C., Kamdar, K., Wu, M.-F., Leung, K., Kennedy-
Nasser, A., Craddock, J., Ahmed, N., Gottschalk, S., Bollard, C.,
Brenner, M., Heslop, H., McClain, K., Krance, R. Baylor College of Med-
icine, Houston, TX
Background:Hemophagocytic lymphohistiocytosis (HLH) is a syn-
drome characterized by pathologic inflammation that is almost uni-
versally fatal without immune modulating and cytotoxic
chemotherapy. Patients with familial HLH or inflammation uncon-
trolled by medical therapy require stem cell transplant.We reviewed
the clinical courses of 26 consecutive patients who underwent first
stem cell transplant for HLH to evaluate outcomes and identify clin-
ical factors associated with engraftment and survival.
Methods: Medical records of all children receiving stem cell trans-
plant for HLH at Texas Children’s Hospital (TCH) from 2000-
2010 were reviewed.
Results: The median time from onset of HLH symptoms to initial
chemotherapy was 31 days, with a median time to transplant of
148 days. Many patients had pre-transplant morbidity, with 26%
having a Lansky score 80 or less, and 50% demonstrating clinical
or lab evidence of inflammation at the start of conditioning. Re-
duced-intensity conditioning was used for 32% of the transplants.
Transplant-related morbidity included high rates of engraftment
syndrome (28%), veno-occlusive disease (24%), seizure (16%), acute
bleeding (12%), CMV reactivation (48%), EBV reactivation (12%),
adenovirus infection (28%), severe mucositis (64%) and acute graft
versus host disease (GVHD) (32%). Median time to engraftment
was 17.5 days, and there was a high rate of eventual graft failure
(21%). Day 100 survival was 81% (95% CI 64-94%), 1 year survival
was 61% (95%CI 38-77%), with a longer term survival of 58% (143
days–10 years) and most recent Lansky score . 90 for all survivors.
Conclusions: While stem cell transplant is essential for survival in
patients with familial and refractory disease HLH, it also results in
